1. ALLA AKTIER
  2. NYHETER
  3. BONESUPPORT

Bonesupport

Nyheter Bonesupport Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

BONESUPPORT invites to a Capital Markets Day, September 1, 2022

BONESUPPORT AB invites investors, analysts and media to a Capital Markets Day in Stockholm on Thursday, September 1, 2022 at 14.00-16.30.

The focus of the Capital Markets Day is the US launch of BONESUPPORT's antibiotic eluting product CERAMENT G, which recently received market authorization from the US FDA. Some of the speakers will be Professor Anand Pillai who is responsible for several studies with CERAMENT, Michael Diefenbeck, Chief Medical Officer at BONESUPPORT, and Mike Roth, General Manager and EVP Commercial Operations for North America at BONESUPPORT.

Date: 1 September 2022
Time: 2:00 p.m. to 4:30 p.m
Place: Helio GT30, Grev Turegatan 30, Stockholm

There will be some 80 physical slots available. For physical slots please register at: https://financialhearings.com/event/44406

Follow the event digitally at https://tv.streamfabriken.com/bonesupport-cmd-2022

Welcome!

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

BONESUPPORT invites to a Capital Markets Day, September 1, 2022

Datum 2022-08-16, kl 08:50
Källa MFN
Bifogade filer
BONESUPPORT invites to a Capital Markets Day, September 1, 2022